arrow
K

Kristoffer Staal Rohrberg

Rigshospitalet
H指数:19
被引数:2,385

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model

内源性逆转录病毒靶向免疫疗法治疗非小细胞肺癌,细胞HERV-K表达支持,以及ERV疗法在动物模型中的依赖性和疗效

2026-10-300
OA
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Werner解旋酶抑制剂用于高级别微卫星不稳定性实体瘤:一项1期临床试验

2026-09-290
OA
Engineering human endogenous retrovirus-K for improving immunogenicity and broad cancer targeting

工程化改造人类内源性逆转录病毒-K以提高免疫原性和广泛癌症靶向性

2026-09-240
OA
Scalable clinical proteomics from DNA/RNA extraction flowthroughs enables integrated proteogenomic profiling from a single cancer biopsy

从DNA/RNA提取滤液中实现可扩展的临床蛋白质组学,可从单个癌症活检中实现整合的蛋白质基因组学分析

2026-09-200
OAAI
Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids

组织学保真度和转移性患者来源类器官的微环境激酶组特征

2026-04-030
OAAI
Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform

精准癌症医学平台中患者匹配类器官药物反应的免疫细胞调节

Cells
IF5.2
2026-01-300
OAAI
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

晚期实体瘤患者AXL特异性抗体药物偶联物Enapotamab Vedotin的I/II期研究

2025-11-010
OA
Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access

克服阻碍先进生物分子技术发展的壁垒,以指导实体瘤治疗:一条获取途径的路线图

2025-05-080
PRE
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma

EGFRvIII x CD3 双特异性抗体在 newly diagnosed glioblastoma 治疗中的首次人体研究

2025-01-011
OAAI
From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis

从乳腺癌和胃癌到更广阔领域:利用定量RNA和蛋白质分析扩展实体瘤中HER2的检测

2024-09-010
PRE
A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors

一项关于BI 1910(一种针对TNFR2的单克隆抗体激动剂)的I/IIa期首次人体I期研究,作为单一药物以及与pembrolizumab联用,用于治疗晚期实体瘤患者。

2024-09-010
PRE
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

CEA阳性实体瘤患者CEA-CD3双特异性抗体cibisatamab加或不加阿特珠单抗: 两项多机构1期试验的结果

2024-05-154
OAAI
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
2024-04-173
OAAI
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition

改进: 通过大规模验证T细胞识别来预测新表位免疫原性的特征模型

2024-04-034
OAAI
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
2024-02-062
PRE